Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 13/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.56 |
| ▸ | MAOA | P21397 | 9/20 | 0.51 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20569292 | 0.91 | MAOB (0.63) | MAOBHRH3MAOA | |
| SCHEMBL30103244 | 0.87 | HRH3 (0.56) | MAOBHRH3MAOA | |
| SCHEMBL4815741 | 0.86 | MAOB (0.63) | MAOBHRH3MAOA | |
| SCHEMBL27829011 | 0.84 | MAOB (0.66) | MAOBHRH3MAOA | |
| SCHEMBL1915443 | 0.83 | MAOB (0.60) | MAOBHRH3MAOACASP1CASP7 | |
| SCHEMBL268592 | 0.81 | KDM4E (0.56) | MAOBHRH3CASP1CASP7HSD17B10 | |
| SCHEMBL14604954 | 0.81 | MAOB (0.65) | MAOBHRH3MAOA | |
| SCHEMBL8272631 | 0.81 | MAOB (0.69) | MAOBHRH3MAOA | |
| SCHEMBL29090878 | 0.80 | MAOB (0.60) | MAOBHRH3MAOACASP1CASP7 | |
| Water SCHEMBL28454486 | 0.80 | KDM4E (0.54) | MAOBHRH3CASP1CASP7HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220380378-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | ESSA PHARMA INC. (CA) | 2022-12-01 | — | — | US | disclosed |
| US-20120035196-A1 | CARBOXYLIC ACID COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-09 | — | — | US | disclosed |
| US-20120035196-A1 | CARBOXYLIC ACID COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-09 | — | — | US | disclosed |
| WO-1992021661-A1 | CYCLIC ANTITUMOR COMPOUNDS | GLAXO INC. (US) | 1992-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380378-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | AR, NR5A1, ESRRA | MAOB 594/4885HRH3 2948/4885MAOA 580/4885 |
| US-20120035196-A1 | CARBOXYLIC ACID COMPOUND | GPR119, GPR65, GPR55 | MAOB 3576/4885HRH3 766/4885MAOA 3319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.